Integral Health Asset Management LLC Acquires New Stake in AstraZeneca PLC (NASDAQ:AZN)

Integral Health Asset Management LLC acquired a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 225,000 shares of the company’s stock, valued at approximately $14,742,000. AstraZeneca comprises approximately 1.3% of Integral Health Asset Management LLC’s portfolio, making the stock its 28th largest holding.

A number of other large investors have also made changes to their positions in the stock. Banque Transatlantique SA purchased a new position in AstraZeneca during the fourth quarter worth about $26,000. Albion Financial Group UT lifted its position in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after buying an additional 248 shares during the period. CoreCap Advisors LLC lifted its position in AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after buying an additional 155 shares during the period. Golden State Wealth Management LLC purchased a new position in AstraZeneca during the fourth quarter worth about $55,000. Finally, Crews Bank & Trust purchased a new position in AstraZeneca during the fourth quarter worth about $55,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AZN. BNP Paribas began coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective on the stock. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a report on Thursday, February 13th. Finally, Morgan Stanley began coverage on AstraZeneca in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Buy” and an average target price of $88.00.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN opened at $67.57 on Monday. The company has a market cap of $209.55 billion, a P/E ratio of 29.90, a PEG ratio of 1.42 and a beta of 0.40. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68. The business’s 50-day simple moving average is $71.33 and its 200 day simple moving average is $69.65.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.10 by $0.14. The business had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company’s revenue was up 7.2% on a year-over-year basis. During the same period last year, the business posted $2.06 EPS. On average, sell-side analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.